Skip to main content

Patient Access

By Jessica Hagen | 03:44 pm | June 27, 2025
The company offers mental healthcare for children and their families and will use the funds to expand its reach.
By Jessica Hagen | 12:24 pm | June 27, 2025
The announcement comes the same week the pharma giant ended its collaboration with Hims & Hers to sell Wegovy, alleging the company engages in deceptive marketing and illegally sells copycat drugs.
By Anthony Vecchione | 05:34 pm | June 26, 2025
Christopher McGhee says that, along with the acquisition, Current Health will have a "return to scrappiness and that startup spirit."
By Jessica Hagen | 05:09 pm | June 26, 2025
The company offers an AI-enabled workflow automation platform for administrative tasks pertaining to specialty medications. 
By Jessica Hagen | 12:00 pm | June 26, 2025
Connor Glass, founder and CEO of Phantom Neuro, discusses the company's muscle-machine interface that allows individuals with limb loss to control robotic limbs and systems using electrical activity from their own muscles.
HIMSS25
By HIMSS TV | 04:21 pm | June 24, 2025
Joan Webley of Hospitals Without Borders, which provides modular hospitals and clinics to regions in need, says attending HIMSS25 helped her gain insights and connect with people interested in the organization's mission.
By HIMSS TV | 07:10 pm | June 23, 2025
Eversana senior vice president of health innovation, Alberta Spreafico, discusses the company's collaboration with the Digital Therapeutics Alliance to analyze frameworks and map reimbursement pathways in Europe for digital health adoption.
By Jessica Hagen | 03:19 pm | June 23, 2025
The vision-restoring device will be implanted in humans within six to 12 months, following a successful monkey implantation that has remained active for three years, Musk said.
By Jessica Hagen | 12:12 pm | June 19, 2025
In March, the company received FDA marketing authorization for the first at-home test to detect chlamydia, gonorrhea and trichomoniasis.
By Jessica Hagen | 05:08 pm | June 17, 2025
The company's valuation has increased by $1 billion since its $130 million Series E funding round last year.